DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive interim results from Part 1a of its Phase 2 study of DM199 for the treatment of preeclampsia. The study, which is open-label and investigator-sponsored, demonstrated statistically significant reductions in both systolic and diastolic blood pressure, as well as a significant reduction in the uterine artery pulsatility index. Importantly, DM199 did not cross the placental barrier and was generally safe and well-tolerated. The study achieved pre-specified safety and efficacy endpoints, reinforcing DM199's therapeutic potential as a first-in-class, disease modifying therapy for preeclampsia. Currently, there are no approved pharmacological treatments for preeclampsia in the United States and Europe. DiaMedica Therapeutics plans to discuss these interim results further during a conference call and webcast scheduled for July 17, 2025.